ATE555106T1 - Cyclohexancarbonsäureverbindung - Google Patents

Cyclohexancarbonsäureverbindung

Info

Publication number: ATE555106T1
Authority: AT; Austria
Prior art keywords: acid compound; cyclohexanecarbonic; cyclohexanecarbonic acid; pyrrolidinylmethoxy; indolylcarbonyl
Prior art date: 2003-07-24

Application number

AT04747846T

Other languages

English (en)

Inventor

Makoto Ono

Shigeru Noguchi

Original Assignee

Daiichi Sankyo Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-24

Filing date

2004-07-23

Publication date

2012-05-15

2004-07-23 Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd

2012-05-15 Application granted granted Critical

2012-05-15 Publication of ATE555106T1 publication Critical patent/ATE555106T1/de

Links

239000002253 acid Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
-1 1-methyl-1H-3-indolylcarbonyl Chemical group 0.000 abstract 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 abstract 1
108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000007774 longterm Effects 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
229910052708 sodium Inorganic materials 0.000 abstract 1
239000011734 sodium Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Indole Compounds (AREA)

AT04747846T 2003-07-24 2004-07-23 Cyclohexancarbonsäureverbindung ATE555106T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2003201062		2003-07-24
PCT/JP2004/010457 WO2005009992A1 (ja)	2003-07-24	2004-07-23	シクロヘキサンカルボン酸類

Publications (1)

Publication Number	Publication Date
ATE555106T1 true ATE555106T1 (de)	2012-05-15

Family

ID=34100472

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04747846T ATE555106T1 (de)	2003-07-24	2004-07-23	Cyclohexancarbonsäureverbindung

Country Status (12)

Country	Link
US (2)	US7691894B2 (de)
EP (1)	EP1650205B1 (de)
JP (1)	JP4676884B2 (de)
KR (1)	KR101051842B1 (de)
CN (1)	CN1826336B (de)
AT (1)	ATE555106T1 (de)
CA (2)	CA2528586A1 (de)
ES (1)	ES2382806T3 (de)
IL (1)	IL172443A0 (de)
MX (1)	MXPA06000850A (de)
TW (1)	TWI340134B (de)
WO (1)	WO2005009992A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2528586A1 (en) *	2003-07-24	2005-02-03	Daiichi Pharmaceutical Co., Ltd.	Cyclohexanecarboxylic acid compound
EP1961750B1 (de)	2005-12-13	2013-09-18	Daiichi Sankyo Company, Limited	Vla-4-hemmendes arzneimittel
US8702640B2 (en) *	2007-08-17	2014-04-22	The Invention Science Fund I, Llc	System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US8753304B2 (en) *	2007-08-17	2014-06-17	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8460229B2 (en)	2007-08-17	2013-06-11	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US8162924B2 (en)	2007-08-17	2012-04-24	The Invention Science Fund I, Llc	System, devices, and methods including actively-controllable superoxide water generating systems
US8734718B2 (en) *	2007-08-17	2014-05-27	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US20090163977A1 (en) *	2007-08-17	2009-06-25	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System, devices, and methods including sterilizing excitation delivery implants with cryptographic logic components
US8366652B2 (en) *	2007-08-17	2013-02-05	The Invention Science Fund I, Llc	Systems, devices, and methods including infection-fighting and monitoring shunts
US8647292B2 (en) *	2007-08-17	2014-02-11	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US20090177254A1 (en) *	2007-08-17	2009-07-09	Searete Llc, A Limited Liability Of The State Of The State Of Delaware	System, devices, and methods including actively-controllable electrostatic and electromagnetic sterilizing excitation delivery system
US8706211B2 (en) *	2007-08-17	2014-04-22	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having self-cleaning surfaces
US20110160644A1 (en) *	2007-08-17	2011-06-30	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems, devices, and methods including catheters configured to release ultraviolet energy absorbing agents
US20090163964A1 (en) *	2007-08-17	2009-06-25	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	System, devices, and methods including sterilizing excitation delivery implants with general controllers and onboard power
US20090048648A1 (en) *	2007-08-17	2009-02-19	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Self-sterilizing device
US20110152751A1 (en) *	2008-12-04	2011-06-23	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems, devices, and methods including catheters having UV-Energy emitting coatings
US8585627B2 (en) *	2008-12-04	2013-11-19	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
WO2010065135A1 (en) *	2008-12-04	2010-06-10	Searete, Llc	System, devices, and methods including actively-controllable sterilizing excitation delivery implants
US9474831B2 (en)	2008-12-04	2016-10-25	Gearbox, Llc	Systems, devices, and methods including implantable devices with anti-microbial properties
ES3013256T3 (en)	2018-10-30	2025-04-11	Gilead Sciences Inc	Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
JP7189368B2 (ja)	2018-10-30	2022-12-13	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４ベータ７インテグリンの阻害のための化合物
EP3873605B1 (de)	2018-10-30	2024-10-23	Gilead Sciences, Inc.	Verbindungen zur inhibierung von alpha4-beta7-integrin
FI3873884T3 (fi)	2018-10-30	2025-02-24	Gilead Sciences Inc	3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
WO2021030438A1 (en)	2019-08-14	2021-02-18	Gilead Sciences, Inc.	Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6204261B1 (en)	1995-12-20	2001-03-20	Vertex Pharmaceuticals Incorporated	Inhibitors of interleukin-1β Converting enzyme inhibitors
DE2500157C2 (de)	1975-01-03	1983-09-15	Hoechst Ag, 6230 Frankfurt	N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
DE2706977A1 (de)	1977-02-18	1978-08-24	Hoechst Ag	Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
DE3063878D1 (en)	1979-07-13	1983-07-28	Thomae Gmbh Dr K	Derivatives of carboxylic acids, their preparation and medicaments containing them
JPS60181081A (ja)	1984-02-29	1985-09-14	Kaken Pharmaceut Co Ltd	新規ビスベンゾフラニルケトン誘導体
JPH04112868A (ja)	1990-09-03	1992-04-14	Otsuka Pharmaceut Co Ltd	置換ヘテロ環を有するフェニルカルボン酸誘導体
JPH0543574A (ja)	1991-08-13	1993-02-23	Wakamoto Pharmaceut Co Ltd	ヘテロ環置換テトラゾール−１−酢酸誘導体
FR2694295B1 (fr)	1992-07-28	1994-09-02	Adir	Nouveaux peptides dérivés de trifluoromethylcetones, leur procéde de préparation et les compositions pharmaceutiques qui les contiennent.
ES2103181B1 (es)	1994-08-01	1998-04-01	Menarini Lab	Amidas naftalenicas con accion antagonista de los leucotrienos.
GB9408936D0 (en)	1994-05-05	1994-06-22	Cancer Res Inst	Anti-cancer compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
CA2225666A1 (en)	1995-06-30	1997-01-23	Smithkline Beecham Corporation	Use of stat 5 sh2 domain specific compounds to enhance erythropoiesis
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
NZ333904A (en)	1996-07-25	2000-06-23	Biogen Inc	VLA-4 and IIb/IIIa cell adhesion inhibitors
JP2000516958A (ja)	1996-08-26	2000-12-19	ジェネティックス・インスチチュート・インコーポレーテッド	ホスホリパーゼ酵素の阻害剤
DE19647381A1 (de)	1996-11-15	1998-05-20	Hoechst Ag	Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
JP2001505204A (ja)	1996-11-22	2001-04-17	エラン・ファーマシューティカルズ・インコーポレイテッド	Ｎ―（アリール／ヘテロアリールアセチル）アミノ酸エステル、それを含有する医薬組成物および該化合物を用いてβ―アミロイドペプチドの放出および／または合成を阻害する方法
US6117901A (en)	1996-11-22	2000-09-12	Athena Neurosciences, Inc.	N-(aryl/heteroarylacetyl) amino acid esters, pharmaceutical compositions comprising same, and methods for use
IL136584A (en)	1997-12-23	2005-03-20	Aventis Pharma Ltd	SUBSTITUTED beta-ALANINES, PHARMACEUTICAL COMPOSITIONS COMPRISING THEM AND USES THEREOF
HUP0100156A3 (en)	1998-02-25	2002-12-28	Genetics Inst Inc Cambridge	Indole derivatives as inhibitors of phospholipase a2 and use of them for producing pharmaceutical compositions
NZ509199A (en)	1998-05-28	2003-10-31	Biogen Inc	A VLA-4 inhibitor: oMePUPA-V
CA2334476A1 (en)	1998-06-08	1999-12-16	Ajinomoto Co., Inc.	Benzamidine derivative
SK20052000A3 (sk)	1998-06-30	2002-08-06	Pfizer Products Inc.	Nepeptidové inhibítory VLA-4 dependentnej bunkovej väzby použiteľné pri liečení zápalových, autoimunitných a respiračných chorôb
JP2002521375A (ja)	1998-07-23	2002-07-16	アストラゼネカアクチエボラーク	化合物
GB9916374D0 (en)	1998-07-23	1999-09-15	Zeneca Ltd	Chemical compounds
US6608084B1 (en)	1998-08-26	2003-08-19	Aventis Pharma Ltd.	Aza-bicycles which modulate the inhibition of cell adhesion
GB9821199D0 (en)	1998-09-30	1998-11-25	Glaxo Group Ltd	Chemical compounds
US6429132B1 (en)	1998-12-23	2002-08-06	Aurora Systems, Inc.	Combination CMP-etch method for forming a thin planar layer over the surface of a device
US6207700B1 (en)	1999-01-07	2001-03-27	Vanderbilt University	Amide derivatives for antiangiogenic and/or antitumorigenic use
WO2000049005A1 (en)	1999-02-16	2000-08-24	Aventis Pharma Limited	Bicyclic compounds and their use as integrin receptor ligands
JP2000344666A (ja)	1999-04-01	2000-12-12	Sankyo Co Ltd	糖及び脂質代謝改善剤
ES2231179T3 (es)	1999-04-12	2005-05-16	Aventis Pharma Limited	Compuestos de heteroarilo biciclicos sustituidos como antagonistas de la integrina.
CA2372836C (en)	1999-05-05	2009-01-20	Aventis Pharma Limited	Substituted pyrrolidines as cell adhesion inhibitors
ES2321055T3 (es)	1999-05-05	2009-06-02	Aventis Pharma Limited	Compuestos biblicos sustituidos.
EP1176959B1 (de)	1999-05-05	2006-03-08	Merck & Co., Inc.	Neue prolinverbindungen als mikrobizide mittel
CN1391473A (zh)	1999-06-30	2003-01-15	第一制药株式会社	Vla－4抑制剂化合物
CZ2002518A3 (cs)	1999-08-13	2002-05-15	Biogen, Inc.	Inhibitory buněčné adheze a farmaceutické prostředky, které je obsahují
EP1263726B1 (de)	1999-11-10	2007-09-26	Sanofi-Aventis Deutschland GmbH	N-acylpyrrolidin-2-ylalkylbenzamidin-derivate als inhibitoren von factor xa
YU41202A (sh)	1999-12-28	2005-03-15	Pfizer Products Inc.	Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
GB0001346D0 (en)	2000-01-21	2000-03-08	Astrazeneca Uk Ltd	Chemical compounds
DE10006453A1 (de)	2000-02-14	2001-08-16	Bayer Ag	Piperidylcarbonsäuren als Integrinantagonisten
GB0004686D0 (en)	2000-02-28	2000-04-19	Aventis Pharma Ltd	Chemical compounds
AU2001235806A1 (en)	2000-03-01	2001-09-12	Aventis Pharma Limited	2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors
US6448281B1 (en)	2000-07-06	2002-09-10	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
CN1620433A (zh)	2000-07-19	2005-05-25	霍夫曼-拉罗奇有限公司	作为内皮肽转化酶抑制剂的吡咯烷衍生物
JP4212358B2 (ja) *	2000-12-28	2009-01-21	第一三共株式会社	Ｖｌａ−４阻害薬
GB2377933A (en)	2001-07-06	2003-01-29	Bayer Ag	Succinic acid derivatives useful as integrin antagonists
WO2004099136A1 (ja) *	2003-05-09	2004-11-18	Daiichi Pharmaceutical Co., Ltd.	ピロリジン誘導体の製造方法
CA2528586A1 (en) *	2003-07-24	2005-02-03	Daiichi Pharmaceutical Co., Ltd.	Cyclohexanecarboxylic acid compound

2004
- 2004-07-23 CA CA002528586A patent/CA2528586A1/en not_active Abandoned
- 2004-07-23 KR KR1020067001503A patent/KR101051842B1/ko not_active Expired - Fee Related
- 2004-07-23 ES ES04747846T patent/ES2382806T3/es not_active Expired - Lifetime
- 2004-07-23 AT AT04747846T patent/ATE555106T1/de active
- 2004-07-23 WO PCT/JP2004/010457 patent/WO2005009992A1/ja not_active Ceased
- 2004-07-23 US US10/562,122 patent/US7691894B2/en not_active Expired - Fee Related
- 2004-07-23 MX MXPA06000850A patent/MXPA06000850A/es unknown
- 2004-07-23 CA CA2770493A patent/CA2770493A1/en not_active Abandoned
- 2004-07-23 EP EP04747846A patent/EP1650205B1/de not_active Expired - Lifetime
- 2004-07-23 JP JP2005512024A patent/JP4676884B2/ja not_active Expired - Fee Related
- 2004-07-23 TW TW093122176A patent/TWI340134B/zh not_active IP Right Cessation
- 2004-07-23 CN CN2004800212300A patent/CN1826336B/zh not_active Expired - Fee Related
2005
- 2005-12-07 IL IL172443A patent/IL172443A0/en unknown
2009
- 2009-10-07 US US12/574,907 patent/US7893279B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TW200517374A (en)	2005-06-01
US20100022783A1 (en)	2010-01-28
CA2770493A1 (en)	2005-02-03
ES2382806T3 (es)	2012-06-13
MXPA06000850A (es)	2006-03-30
US7691894B2 (en)	2010-04-06
WO2005009992A1 (ja)	2005-02-03
CN1826336B (zh)	2010-06-02
EP1650205A4 (de)	2010-04-28
KR101051842B1 (ko)	2011-07-25
IL172443A0 (en)	2006-04-10
HK1091484A1 (en)	2007-01-19
CA2528586A1 (en)	2005-02-03
EP1650205B1 (de)	2012-04-25
US7893279B2 (en)	2011-02-22
EP1650205A1 (de)	2006-04-26
TWI340134B (en)	2011-04-11
JPWO2005009992A1 (ja)	2006-09-07
US20070105936A1 (en)	2007-05-10
CN1826336A (zh)	2006-08-30
JP4676884B2 (ja)	2011-04-27
KR20060037394A (ko)	2006-05-03

Publication	Publication Date	Title
ATE555106T1 (de)	2012-05-15	Cyclohexancarbonsäureverbindung
DK1392642T3 (da)	2010-03-08	Hidtil ukendte forbindelser som anti-inflammatoriske, immunmodulatoriske og antiproliferative midler
ATE227264T1 (de)	2002-11-15	Metalloproteinase-inhibitoren
TR200001876T2 (tr)	2000-11-21	HIV proteaz inhibitörünün bisülfat tuzu.
CY1113578T1 (el)	2016-06-22	2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
CY1108731T1 (el)	2014-04-09	Ενωσεις σπιροϊνδενιου και σπιροϊνδανιου
SE0100902D0 (sv)	2001-03-15	Compounds
NO20034660D0 (no)	2003-10-17	Spiropyrazolforbindelser
CY1111867T1 (el)	2015-11-04	Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
DE60214392D1 (de)	2006-10-12	1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
CY1106425T1 (el)	2011-10-12	Ενωσις βενζυλαμινης και φαρμακευτικη χρησις αυτης
AR044706A2 (es)	2005-09-21	Procedimientos para preparar 4-aminoquinolinas, inhibidores de cetp
ATE403431T1 (de)	2008-08-15	Benzimidazolon-verbindungen
MXPA03006224A (es)	2004-10-15	Inhibidores de cruzipaina y otras proteasas de cisteina.
NO20052907L (no)	2005-09-12	Sykloalkylendikarboksylsyreforbindelser som antiinflammatoriske, immunmodulatoriske og antiproliferative midler
SE0103710D0 (sv)	2001-11-07	Compounds
BR0307339A (pt)	2004-12-07	Metabolitos de ácido (3-{[(4-terc-butil-benzil)-(piridina-3-sulfonil)-amino]-m etil}-fenóxi)-acético
DK1349578T3 (da)	2006-11-27	Kombinationspræparat indeholdende en biguanin (metformin) og arginin
ATE356114T1 (de)	2007-03-15	Inhibitoren von metalloproteinasen
HRP20030653B1 (en)	2012-06-30	Novel benzoylguanidine salt
ATE427934T1 (de)	2009-04-15	Nicht-peptidische brs-3-agonisten
SE0101323D0 (sv)	2001-04-12	New process
GT199900116A (es)	2001-01-13	Isoquinolinas.
BR0108146A (pt)	2004-01-06	Processo e intermediários para o preparo de inibidores da protease retroviral
MXPA04003478A (es)	2004-07-30	Sintesis de (4-bromofenil)(4-piperidil)metanona-(z)-o-etiloxima y sales.